Insider Cluster (4 insiders) ·Filed Apr 9, 2026

DNA

Ginkgo Bioworks Holdings, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago
Insider cluster: 4 insiders, $2.5M total
Actionable Insight ▼ Bearish

The scale of insider selling (~0.5% of market cap) by multiple executives and a major shareholder raises concerns about confidence in near-term prospects. Monitor for follow-up filings or downward revisions in guidance that could confirm negative sentiment.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
DNA ▲ +57.23% at T+60d
SHORT call ✗ call lost -57.23% · α vs SPY -46.45% · entry $6.43 → $10.11
Entry anchored
Apr 8, 03:59 PM ET
via exchange tick
T+1d
+0.31%
call -0.31% · α -0.37%
$6.45
settled 6mo ago
T+5d
+23.64%
call -23.64% · α -20.45%
$7.95
settled 6mo ago
T+20d
+56.77%
call -56.77% · α -49.20%
$10.08
settled 5mo ago
T+60d
+57.23%
call -57.23% · α -46.45%
$10.11
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Four insiders, including executives and a 10% owner, sold $2.52M in shares over a 7-day period, with open-market sales averaging $6.41–$6.43 per share. The activity follows a prior cluster involving derivative exercises and a small open-market sale by the same insider.

Key Financial Metrics

Direction
selling
Total Value
$2.5M
Insiders
4

Key Facts

  • Insider cluster involves $2.52M in total open-market sales over 7 days
  • Sellers include executives Jason R. Kelly and Reshma P. Shetty, plus 10% owner Barry Canton
  • Average sale price: ~$6.41–$6.43, totaling 392.2K shares sold
  • All transactions are open-market sales (S code), not non-cash events
  • Total value represents ~0.51% of $497M market cap — modest but notable

Financial Impact

$2.52 million in open-market sales by insiders

insider sentimentmarket confidenceshare supply

Risk Factors

  • Insider selling may signal lack of confidence in current valuation or upcoming results
  • Potential for increased selling pressure if other holders follow suit

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Genomics & Gene Editing

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-DNA-1776718985742
3 reports for DNA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for DNA — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
144
NEUTRAL ★ 2/10
$6.99 $7.88▲ +12.73%▲ +11.91%$12.10 (+73.18%)
Apr 9, 2026
25w ago
Insider Cluster
BEARISH ★ 6/10
$6.43 $7.95▼ −23.64%▼ −20.45%$12.10 (−88.26%)
Apr 9, 2026
25w ago
Insider Cluster
BEARISH ★ 6/10
$6.43 $7.95▼ −23.64%▼ −20.45%$12.10 (−88.26%)
Showing 3 of 3

US Market Status

Market Open — Closes in 2h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 20, 2026